Ovarian cancer screening--current status, future directions

Area of Science:

• Oncology
• Gynecologic Oncology
• Cancer Screening Research

Background:

• Current ovarian cancer (OC) screening methods, including the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial using CA125 and transvaginal ultrasound, have not shown a mortality benefit.
• The United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) employs the Risk of Ovarian Cancer (ROC) time series algorithm for CA125 interpretation, showing promise in sensitivity and specificity, with mortality data pending.

Purpose of the Study:

• To explore the impact of evolving insights into ovarian cancer aetiology and evolution on future screening strategies.
• To discuss the role of biomarker discovery in advancing ovarian cancer detection and management.

Main Methods:

• Review of existing ovarian cancer screening trial data (PLCO, UKCTOCS).
• Analysis of the potential of novel biospecimens (e.g., cervical cytology) and targeted imaging.
• Exploration of time series algorithms for interpreting biomarker profiles.

Main Results:

• Past screening trials (PLCO) have failed to establish a mortality benefit for ovarian cancer.
• The ROC algorithm in UKCTOCS shows encouraging sensitivity and specificity for ovarian cancer detection.

Conclusions:

• A deeper understanding of ovarian cancer's biological underpinnings is crucial for developing effective screening.
• Future ovarian cancer screening may involve a multi-modal approach, integrating advanced biomarkers, novel biospecimens, targeted imaging, and sophisticated data analysis algorithms for early, low-volume disease detection.